Related Experiment Video
Updated: May 21, 2026
Quantitative Measurement of Intrathecally Synthesized Proteins in Mice
Published on: November 29, 2019
Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease
C E Teunissen1, M Sombekke, L van Winsen
1Department of Clinical Chemistry, VU University Medical Center, The Netherlands. c.teunissen@vumc.nl
Background:
Oxidative stress plays an important role in multiple sclerosis (MS). Isoprostanes are biomarkers for oxidative stress and have been related to neurological disease progression.
Objective:
To study whether plasma isoprostane levels were related to disease progression in MS.
Methods:
Plasma levels of 8,12-iso-iPF2alpha-VI were determined in 17 patients with clinically isolated syndrome (CIS), 41 relapsing-remitting MS (RRMS) patients and 5 primary progressive MS (PPMS) patients and related to MRI and clinical disease parameters.
Results:
Isoprostane levels were similar in CIS (60.9, interquartile range (IQR): 47.7-77.7 pg/ml) and RRMS patients (65.3, IQR: 51.9-82.8 pg/ml). The plasma levels were lower in PPMS patients (42.5, IQR: 37.1-49.9) pg/ml, p<0.05) compared to CIS and RRMS patients in this cohort, which was not confirmed in a second cohort. Baseline isoprostane levels were not related to clinical progression defined by conversion form CIS to RRMS or change in Expanded Disability Status Scale (EDSS) or MS Functional Composite (MSFC) scores during six years of follow-up (CIS + RRMS), nor to change in volume of gadolinium enhancing lesions, T2 lesion load or T1 hypointense lesion load during 2.8 years of follow-up (CIS + RRMS).
Conclusion:
These results do not support a strong role of 8,12-iso-iPF2alpha-VI in the prediction of disease progression in MS.
Insights
Plasma isoprostane levels did not strongly predict multiple sclerosis (MS) progression. This study found no significant relationship between these oxidative stress biomarkers and disease worsening in MS patients.
Area of Science:
- Neuroimmunology
- Biomarkers
- Oxidative Stress
Background:
- Oxidative stress is implicated in multiple sclerosis (MS) pathogenesis.
- Isoprostanes serve as biomarkers for oxidative stress and have been linked to neurological disease progression.
Purpose of the Study:
- To investigate the association between plasma isoprostane levels and disease progression in multiple sclerosis (MS).
Main Methods:
- Plasma 8,12-iso-iPF2alpha-VI levels were measured in patients with clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and primary progressive MS (PPMS).
- Levels were correlated with MRI and clinical disease parameters, including disability and lesion load.
Main Results:
- Isoprostane levels were similar in CIS and RRMS patients but lower in PPMS patients in one cohort.
- Baseline isoprostane levels did not correlate with clinical progression (conversion to RRMS, EDSS, MSFC changes) over six years.
- No association was found between isoprostane levels and MRI-derived measures of disease activity (gadolinium-enhancing lesions, T2/T1 lesion load) over 2.8 years.
Conclusions:
- The findings suggest that 8,12-iso-iPF2alpha-VI may not be a strong predictor of disease progression in MS.
- Further research may be needed to explore other isoprostane variants or their role in specific MS subtypes.
